MedDataX Logo

Recommendations for the Treatment of Children With Burkitt's Lymphoma

NCT ID: NCT04425421

Last Updated: 2025-10-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-11-01

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for the stage IV disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Thereapeutic Recommendantion for Children With a Hodgkin Lymphoma

NCT05407480

Staging Therapeutic Recommendations
RECRUITING

LBL-2016 for Children or Adolescents in China

NCT02845882

Lymphoblastic Lymphoma
ACTIVE_NOT_RECRUITING PHASE3

TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma

NCT00002757

Leukemia Lymphoma
COMPLETED PHASE3

International Study for Treatment of High Risk Childhood Relapsed ALL 2010

NCT03590171

Acute Lymphoblastic Leukemia (ALL)
RECRUITING PHASE2

Treatment of Burkitt Lymphoma/Leukemia and B Large Cell NHL

NCT00187161

Non-Hodgkin Lymphoma Acute Lymphoblastic Leukemia, Mature B-Cell
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is the 4th Burkitt's Lymphoma (LMB) study by the GFAOP group. This study hopes to include at least 14 Sub Saharian countries some of whom have never participated in a LMB study. The evaluation of improvement in early diagnosis should be possible in this study. The study hopes to be able to evaluate children earlier, with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for children with a stage IV disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Burkitt Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OBSERVATIONAL

OBSERVAITON OF THE CAPACITY OF THE GROUP TO TREAT ACCORDING TO THE PROTOCOLE AND LOOK AT OUTCOME FOR STAGE I AND II DISEASE

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Clinical diagnosis of Burkitt's Lymphoma: all location. Diagnosis by cytology or histology. Not possible to follow all the treatment.

\-

Exclusion Criteria

Not a B Cell tumor. Child has been previously treated. Child has also another illness which would render the treatment incompatible. Parents refusal.
Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

French Africa Pediatric Oncology Group

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hopital Yalgado Ouedraogo

Ouagadougou, , Burkina Faso

Site Status RECRUITING

CHU de Treichville à ABIDJAN

Abidjan, , Côte d’Ivoire

Site Status RECRUITING

Cliniques Universitaires de Kinshasa

Kinshasa, Kinshasa City, Democratic Republic of the Congo

Site Status RECRUITING

Cliniques Universitaires de Lubumbashi (CUL)

Lubumbashi, , Democratic Republic of the Congo

Site Status RECRUITING

HJRA, Hôpital universitaire Joseph Ravoahangy Andrianavalona

Antananarivo, , Madagascar

Site Status RECRUITING

CHU Gabriel Touré (HGT)

Bamako, , Mali

Site Status RECRUITING

Hôpital Aristide Le Dantec

Dakar, , Senegal

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Burkina Faso Côte d’Ivoire Democratic Republic of the Congo Madagascar Mali Senegal

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Chantal Ms BOUDA, Dr.

Role: CONTACT

[email protected]
00(226)70 10 01 30

BRENDA MALLON, MSc

Role: CONTACT

[email protected]
0033142115411

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

BOUDA CHANTAL, DR

Role: primary

Line Dr COUITCHERE, MD

Role: primary

[email protected]

BUDIONGO Aléine, DR

Role: primary

LUKAMBA Robert, DR

Role: primary

[email protected]
00(243) 814024633

Mbolanirina RAKOTOMAHEFA, Dr

Role: primary

34 14 201 51

BOUBACAR TOGO, PROFESSEUR

Role: primary

[email protected]
+223 66 74 29 04

Fatou-Binetou DIAGNE AKONDE, Dr

Role: primary

00(221)77 637 40 63

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GFA LMB 2019

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Radiation Therapy and the Natural History of Childhood Cancers
NCT00064883 COMPLETED
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
NCT03743246 TERMINATED PHASE1/PHASE2
Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children with Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)
NCT05681260 RECRUITING PHASE3
Bortezomib in Treating Children With Advanced Solid Tumors
NCT00021216 COMPLETED PHASE1
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
NCT05518383 RECRUITING PHASE4
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
NCT04043494 RECRUITING PHASE3
A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL
NCT03971305 UNKNOWN
Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
NCT02847130 COMPLETED
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
NCT00994500 COMPLETED PHASE1
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT02303821 COMPLETED PHASE1
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
NCT00057811 COMPLETED PHASE2
Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma
NCT00418327 COMPLETED PHASE1
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
NCT01175356 COMPLETED PHASE1
Clinical and Therapeutic Impact of Large Genomic Studies at Diagnosis in Pediatric Solid Cancers
NCT06171971 RECRUITING
BNHL-2015 for Children or Adolescents in China
NCT02405676 ACTIVE_NOT_RECRUITING PHASE2/PHASE3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
NCT03126916 RECRUITING PHASE3
Study of Systemic and Spinal Chemotherapy Followed by Radiation for Infants With Brain Tumors
NCT00042367 COMPLETED NA
Project: Every Child for Younger Patients With Cancer
NCT02402244 RECRUITING
Evaluation and Natural History of Children With Cancer and AIDS
NCT00001424 COMPLETED
Observational Trial of the Impact of Radiation Dose in Children With Brain and Skull Base Tumors.
NCT03972514 ACTIVE_NOT_RECRUITING
Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma
NCT02025881 TERMINATED PHASE1/PHASE2
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
NCT02553460 ACTIVE_NOT_RECRUITING PHASE1/PHASE2
Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in Relapse
NCT06649253 RECRUITING NA
Pilot Study of Safety and Toxicity of Acquiring Hyperpolarized Carbon-13 Imaging in Children With Brain Tumors
NCT02947373 COMPLETED PHASE1
LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma
NCT00085150 COMPLETED PHASE1